Free Trial
NASDAQ:PHXM

PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 07/1/2025

About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)

Key Stats

Today's Range
$3.10
$3.10
50-Day Range
$3.10
$3.10
52-Week Range
$2.50
$13.00
Volume
N/A
Average Volume
2,472 shs
Market Capitalization
$10.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PHXM Stock News Headlines

The Pentagon just made a National Security move...
This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.... a consultant who's worked for the likes of J.P. Morgan and Citicorp... into the middle of the Utah desert with a film crew.Why? So he could lead an investigation into a radical new kind of energy that's so abundant, the Dept. of Energy says it could meet America's power needs for the next 2 million years. It's got nothing to do with wind, solar, nuclear, oil or gas.
See More Headlines

PHXM Stock Analysis - Frequently Asked Questions

PHAXIAM Therapeutics' stock was trading at $3.10 at the beginning of the year. Since then, PHXM shares have increased by 0.0% and is now trading at $3.10.
View the best growth stocks for 2025 here
.

PHAXIAM Therapeutics shares reverse split on the morning of Wednesday, September 20th 2023.The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHXM
Employees
49
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.66 million
Price / Cash Flow
N/A
Book Value
$7.98 per share
Price / Book
0.39

Miscellaneous

Free Float
3,346,000
Market Cap
$10.58 million
Optionable
No Data
Beta
2.35
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PHXM) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners